RATIONALE: The pivotal role of phosphoinositide 3-kinase gamma (PI3Kgamma) in leukocyte recruitment makes it an attractive target for immunomodulatory therapy. However, interfering with PI3Kgamma signaling might increase the risk of bacterial infections in humans. OBJECTIVES: We hypothesized that deletion or pharmacologic inhibition of PI3Kgamma would impair the lung inflammatory response to the prototypic gram-positive bacterial pathogen Streptococcus pneumoniae. METHODS: PI3Kgamma knockout (KO) and wild-type mice were infected with S. pneumoniae or challenged with the pneumococcal virulence factor pneumolysin (PLY), and inflammatory leukocyte recruitment, bacterial pathogen elimination, and resolution/repair processes were determined. MEASUREMENTS AND MAIN RESULTS: PI3Kgamma KO mice challenged with PLY responded with lung edema and neutrophilic alveolitis, but showed a drop in alveolar macrophages and failed to recruit exudate macrophages when compared with wild-type mice. S. pneumoniae-infected PI3Kgamma KO mice and wild-type mice pretreated with the pharmacologic inhibitor AS-605240 recruited similar numbers of neutrophils but substantially fewer exudate macrophages into their lungs than control animals. They also displayed a significantly reduced lung pneumococcal clearance and showed an impaired resolution/repair process, leading to progressive pneumococcal pneumonia. CONCLUSIONS: PI3Kgamma gene deletion or pharmacologic inhibition of PI3Kgamma leads to perturbations of critical innate immune responses of the lung to challenge with S. pneumoniae. These data are of clinical relevance for the treatment of chronic inflammatory diseases where pharmacologic inhibition of PI3Kgamma signaling to attenuate effector cell recruitment may have implications for innate immune surveillance of remote organ systems.
RATIONALE: The pivotal role of phosphoinositide 3-kinase gamma (PI3Kgamma) in leukocyte recruitment makes it an attractive target for immunomodulatory therapy. However, interfering with PI3Kgamma signaling might increase the risk of bacterial infections in humans. OBJECTIVES: We hypothesized that deletion or pharmacologic inhibition of PI3Kgamma would impair the lung inflammatory response to the prototypic gram-positive bacterial pathogen Streptococcus pneumoniae. METHODS:PI3Kgamma knockout (KO) and wild-type mice were infected with S. pneumoniae or challenged with the pneumococcal virulence factor pneumolysin (PLY), and inflammatory leukocyte recruitment, bacterial pathogen elimination, and resolution/repair processes were determined. MEASUREMENTS AND MAIN RESULTS:PI3Kgamma KO mice challenged with PLY responded with lung edema and neutrophilic alveolitis, but showed a drop in alveolar macrophages and failed to recruit exudate macrophages when compared with wild-type mice. S. pneumoniae-infectedPI3Kgamma KO mice and wild-type mice pretreated with the pharmacologic inhibitor AS-605240 recruited similar numbers of neutrophils but substantially fewer exudate macrophages into their lungs than control animals. They also displayed a significantly reduced lung pneumococcal clearance and showed an impaired resolution/repair process, leading to progressive pneumococcal pneumonia. CONCLUSIONS:PI3Kgamma gene deletion or pharmacologic inhibition of PI3Kgamma leads to perturbations of critical innate immune responses of the lung to challenge with S. pneumoniae. These data are of clinical relevance for the treatment of chronic inflammatory diseases where pharmacologic inhibition of PI3Kgamma signaling to attenuate effector cell recruitment may have implications for innate immune surveillance of remote organ systems.
Authors: Stefanie Henken; Jennifer Bohling; A David Ogunniyi; James C Paton; Vyvyan C Salisbury; Tobias Welte; Ulrich A Maus Journal: Antimicrob Agents Chemother Date: 2010-06-07 Impact factor: 5.191
Authors: Kathrin Steinwede; Ole Tempelhof; Kristine Bolte; Regina Maus; Jennifer Bohling; Bianca Ueberberg; Florian Länger; John W Christman; James C Paton; Kjetil Ask; Shyam Maharaj; Martin Kolb; Jack Gauldie; Tobias Welte; Ulrich A Maus Journal: J Immunol Date: 2011-10-14 Impact factor: 5.422
Authors: Molly S Thomas; Jason S Mitchell; Christopher C DeNucci; Amanda L Martin; Yoji Shimizu Journal: J Leukoc Biol Date: 2008-06-03 Impact factor: 4.962
Authors: Ines Hahn; Anna Klaus; Ann-Kathrin Janze; Kathrin Steinwede; Nadine Ding; Jennifer Bohling; Christina Brumshagen; Hélène Serrano; Francis Gauthier; James C Paton; Tobias Welte; Ulrich A Maus Journal: Infect Immun Date: 2011-09-12 Impact factor: 3.441
Authors: Wiebke Herbold; Regina Maus; Ines Hahn; Nadine Ding; Mrigank Srivastava; John W Christman; Matthias Mack; Jörg Reutershan; David E Briles; James C Paton; Christine Winter; Tobias Welte; Ulrich A Maus Journal: Infect Immun Date: 2010-04-05 Impact factor: 3.441
Authors: Ines Hahn; Anna Klaus; Regina Maus; John W Christman; Tobias Welte; Ulrich A Maus Journal: Am J Respir Cell Mol Biol Date: 2010-12-22 Impact factor: 6.914
Authors: Christelle P El Haibi; Praveen K Sharma; Rajesh Singh; Paul R Johnson; Jill Suttles; Shailesh Singh; James W Lillard Journal: Mol Cancer Date: 2010-04-22 Impact factor: 27.401